AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis | MicrobiomeTrials← Back to trialsNCT07619638
AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-06-10Est. Completion: 2027-05-30
Enrollment target: 162 participants Locations- Ege University, Izmir, Turkey (Türkiye)
Other microbiome trials you might be interested in
Inflammatory Bowel Disease
Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the…
Chicago, United StatesEst. completion Sep 1, 2026
Ulcerative Colitis (UC)
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that requires regular monitoring of disease activity. Cu…
Asyut, EgyptEst. completion Jan 31, 2027